Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inaticabtagene autoleucel - Juventas Cell Therapy/CASI Pharmaceuticals

Next Previous
Drug Profile

Inaticabtagene autoleucel - Juventas Cell Therapy/CASI Pharmaceuticals

Alternative Names: Anti-CD19 CAR-T cell therapy - Juventas Cell Therapy; CNCT-19; CNTC-19; HI19α-4-1BB-ζ CAR

Latest Information Update: 20 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Medical Sciences
  • Developer CASI Pharmaceuticals; Juventas Cell Therapy
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor B-cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Diffuse large B cell lymphoma
  • Phase I Autoimmune haemolytic anaemia
  • No development reported B-cell lymphoma

Most Recent Events

  • 14 Feb 2025 Juventas Cell Therapy plans to initiate a phase I trial for Autoimmune Thrombocytopenia (Second-line therapy or greater) (NCT06826430)
  • 30 Dec 2024 Juventas Cell Therapy in collaboration with Institute of Hematology & Blood Diseases Hospital completes phase-I/II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in China (IV) (NCT04690192)
  • 07 Dec 2024 Efficacy, adverse event, pharmacokinetics and pharmacodynamics data from phase I trial in Autoimmune haemolytic anaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top